Lilly's tirzepatide clears high bar set by Novo's Wegovy in obesity

The unstoppable march of Eli Lilly’s tirzepatide continues. Having previously shown the dual GIP/GLP-1 agonist reduces the weight of people with diabetes, Lilly has now delivered a hit in its first phase 3 pure play obesity trial, putting Novo Nordisk’s Wegovy on notice that a serious challenger may be on the horizon.